Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Orphan Drug

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1454893

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1454893

Sickle Cell Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

PUBLISHED:
PAGES: 224 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

In the realm of healthcare, the global sickle cell disease treatment market stands as a critical battleground in the fight against this debilitating genetic disorder. However, despite promising developments, the market faces a myriad of challenges hindering its growth trajectory.

MEA Healthcare Infrastructure Struggles:

One of the significant roadblocks impeding the growth of the sickle cell disease treatment market lies in the Middle East and Africa (MEA) region. Here, the lack of robust healthcare infrastructure poses a formidable barrier to effective treatment. Additionally, the inadequate implementation of clinical practice guidelines and a shortage of skilled healthcare professionals further exacerbate the situation.

Access to Treatment in India:

India, a country grappling with a substantial sickle cell disease burden, faces its own set of challenges. The unavailability of essential drugs in rural and tribal areas, coupled with issues of corruption in drug distribution, hampers access to treatment. Moreover, the low disposable income among the affected population impedes their ability to afford necessary medications.

Reimbursement Challenges in Europe:

In Europe, the absence of adequate reimbursement schemes for sickle cell anemia treatment presents a significant hurdle. Despite the high mortality rates associated with the disease, government and insurance companies fail to provide financial support for patients. Consequently, many individuals are forced to forgo treatment due to the prohibitive costs involved, further stalling market growth.

Financial Strain of Treatment:

The financial burden of sickle cell disease treatment looms large, acting as a deterrent to market expansion. The exorbitant costs associated with lifelong therapy, including blood transfusions and bone marrow transplants, place immense strain on both patients and healthcare systems. In regions where reimbursement is lacking, the affordability of treatment becomes a critical issue, hindering market progress.

Regulatory Hurdles in North America:

Even in regions boasting advanced healthcare infrastructure, regulatory hurdles impede market growth. In North America, stringent FDA approval processes limit the availability of approved treatments for sickle cell disease. With only a handful of drugs receiving regulatory clearance, the market faces significant constraints in meeting the needs of patients.

Market Outlook:

Despite these challenges, the global sickle cell disease treatment market remains poised for substantial growth. With a projected Compound Annual Growth Rate (CAGR) of 20%, the segment focusing on sickle cell anemia is expected to lead the market. In particular, indications point to sickle cell anemia capturing over 50% of the market share.

Opportunity Amidst Adversity:

While challenges are present, the market offers substantial opportunities for stakeholders who are prepared to navigate complexities. The absolute dollar opportunity shows notable growth compared to the previous period, with incremental growth expected between the forecast period. This highlights the considerable potential for enterprises to leverage emerging trends and meet unmet needs within the sickle cell disease treatment landscape.

Competitive Analysis:

Key Companies:

  • AstraZeneca Plc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Inc.
  • Baxter International Inc.
  • Emmaus Life Sciences, Inc.
  • Bluebird bio, Inc.
  • Global Blood Therapeutics Inc.
  • Sangamo Therapeutics, Inc.
  • Acceleron Pharma, Inc.
  • Arena Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Others.

Market Segmentation:

By Drug Type

  • Hydroxyurea
  • Antibiotics
  • Pain-relieving Medications
  • Others

By Disease Type

  • Sickle cell anemia
  • Sickle hemoglobin C disease
  • Sickle beta thalassemia
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Latin America
  • Europe Asia Pacific
  • Middle East and Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Sickle Cell Disease Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Sickle Cell Disease Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Sickle Cell Disease Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Hydroxyurea
      • 3.1.1.2. Antibiotics
      • 3.1.1.3. Pain-relieving Medications
      • 3.1.1.4. Others
  • 3.2. Global Sickle Cell Disease Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Sickle cell anemia
      • 3.2.1.2. Sickle hemoglobin C disease
      • 3.2.1.3. Sickle beta thalassemia
      • 3.2.1.4. Others
  • 3.3. Global Sickle Cell Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospital Pharmacies
      • 3.3.1.2. Retail Pharmacies
      • 3.3.1.3. Online Pharmacies
  • 3.4. Global Sickle Cell Disease Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Sickle Cell Disease Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Sickle Cell Disease Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Hydroxyurea
      • 4.1.1.2. Antibiotics
      • 4.1.1.3. Pain-relieving Medications
      • 4.1.1.4. Others
  • 4.2. North America Sickle Cell Disease Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Sickle cell anemia
      • 4.2.1.2. Sickle hemoglobin C disease
      • 4.2.1.3. Sickle beta thalassemia
      • 4.2.1.4. Others
  • 4.3. North America Sickle Cell Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospital Pharmacies
      • 4.3.1.2. Retail Pharmacies
      • 4.3.1.3. Online Pharmacies
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Sickle Cell Disease Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Sickle Cell Disease Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Sickle Cell Disease Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Hydroxyurea
      • 5.1.1.2. Antibiotics
      • 5.1.1.3. Pain-relieving Medications
      • 5.1.1.4. Others
  • 5.2. Europe Sickle Cell Disease Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Sickle cell anemia
      • 5.2.1.2. Sickle hemoglobin C disease
      • 5.2.1.3. Sickle beta thalassemia
      • 5.2.1.4. Others
  • 5.3. Europe Sickle Cell Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospital Pharmacies
      • 5.3.1.2. Retail Pharmacies
      • 5.3.1.3. Online Pharmacies
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Sickle Cell Disease Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Sickle Cell Disease Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Sickle Cell Disease Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Hydroxyurea
      • 6.1.1.2. Antibiotics
      • 6.1.1.3. Pain-relieving Medications
      • 6.1.1.4. Others
  • 6.2. Asia Pacific Sickle Cell Disease Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Sickle cell anemia
      • 6.2.1.2. Sickle hemoglobin C disease
      • 6.2.1.3. Sickle beta thalassemia
      • 6.2.1.4. Others
  • 6.3. Asia Pacific Sickle Cell Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospital Pharmacies
      • 6.3.1.2. Retail Pharmacies
      • 6.3.1.3. Online Pharmacies
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Sickle Cell Disease Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Sickle Cell Disease Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Sickle Cell Disease Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Hydroxyurea
      • 7.1.1.2. Antibiotics
      • 7.1.1.3. Pain-relieving Medications
      • 7.1.1.4. Others
  • 7.2. Latin America Sickle Cell Disease Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Sickle cell anemia
      • 7.2.1.2. Sickle hemoglobin C disease
      • 7.2.1.3. Sickle beta thalassemia
      • 7.2.1.4. Others
  • 7.3. Latin America Sickle Cell Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospital Pharmacies
      • 7.3.1.2. Retail Pharmacies
      • 7.3.1.3. Online Pharmacies
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Sickle Cell Disease Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Sickle Cell Disease Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Sickle Cell Disease Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Hydroxyurea
      • 8.1.1.2. Antibiotics
      • 8.1.1.3. Pain-relieving Medications
      • 8.1.1.4. Others
  • 8.2. Middle East & Africa Sickle Cell Disease Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Sickle cell anemia
      • 8.2.1.2. Sickle hemoglobin C disease
      • 8.2.1.3. Sickle beta thalassemia
      • 8.2.1.4. Others
  • 8.3. Middle East & Africa Sickle Cell Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospital Pharmacies
      • 8.3.1.2. Retail Pharmacies
      • 8.3.1.3. Online Pharmacies
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Sickle Cell Disease Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Sickle Cell Disease Treatment Market by Drug Type, Value (US$Bn), 2018 - 2031
      • 8.4.1.8. Egypt Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Sickle Cell Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Sickle Cell Disease Treatment Market by Disease Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Sickle Cell Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Distribution Channel vs by Disease Type Heat map
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. AstraZeneca Plc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Eli Lilly and Company
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Bristol-Myers Squibb Company
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Novartis AG
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Pfizer Inc.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Baxter International Inc.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Emmaus Life Sciences, Inc.
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Bluebird bio, Inc.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Global Blood Therapeutics Inc.
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Sangamo Therapeutics, Inc.
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. Acceleron Pharma, Inc.
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. Arena Pharmaceuticals, Inc.
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Product Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development
    • 9.4.13. Alnylam Pharmaceuticals, Inc.
      • 9.4.13.1. Company Overview
      • 9.4.13.2. Product Portfolio
      • 9.4.13.3. Financial Overview
      • 9.4.13.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!